NEW YORK (GenomeWeb) – With its adhesive tape technology already implemented in select dermatology offices across the US, DermTech plans to publish an economic study that claims its pigmented lesion assay (PLA) technology will save payors upwards of $700 per melanoma testing procedure.
The firm's non-invasive PLA technology assesses skin cells to distinguish potential melanoma-associated gene expression from benign pigmented skin lesions.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
